Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD Study of AV-380 in Healthy Subjects
NCT04815551Phase 1Completed
- Sponsor
- AVEO Oncology
- Start
- Feb 2021
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rilogrotug in cancer cachexia (8 arms), sponsored by AVEO Oncology. Primary endpoints: Assessment of adverse events (AEs) and treatment emergent adverse events (TEAEs), Injection site safety and tolerability assessment at Day 1 and 7 more. Started Feb 2021; status: completed.
02
Drugs
rilogrotug
03
Conditions
cancer cachexia
Beyond the preview
Go deeper on NCT04815551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04815551.